Dr Guy Pratt is a consultant haematologist with a long-standing research interest in multiple myeloma and chronic lymphocytic leukaemia.
Senior Lecturer in Haematology, School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham.
Background and Research focus
Dr Guy Pratt is an Honorary Consultant Haematologist at the Heart of England NHS Foundation Trust and in the School of Cancer Sciences, University of Birmingham. His main research interests are multiple myeloma and chronic lymphocytic leukaemia (CLL) and he is actively involved in supporting basic research, in developing guidelines, in clinical trials in these diseases and sits on the executive board of the UK Myeloma Forum. Multiple myeloma is the second most common haematological cancer characterized by neoplastic plasma cells accumulating in the bone marrow. Dr Pratt has a long-standing research interest in characterizing tumour specific CD8+ and CD4+ T cells responses and the T cell disturbance in blood and bone marrow in patients afflicted with plasma cell disorders. He is also interested in examining differences in the tumour cell microenvironment in multiple myeloma and the premalignant mono gammopathy of unknown significance (MGUS) state. Collectively, these studies will provide a more in-depth understanding of the pathogenesis of myeloma leading to the development of new and improved treatments. Dr Pratt has also fostered numerous collaborations with national and industry based groups focused on research and developing clinical drugs to treat CLL. In particular, he is currently chief investigator for a national phase I/II clinical trial assessing the efficacy and safety of the drug olaparib, a poly ADP ribose polymerase(parp) inhibitor in CLL.
Haematology; Haemato-Oncology; multiple myeloma; chronic lymphocytic leukaemia; tumour immunotherapy; tumour immunology; T-cell immunity.
Guy is an Honorary Consultant Haematologist at the Heart of England NHS Foundation Trust. As a Consultant Haematologist, he is involved in all aspects of general Haematology but has a particular interest in Haemato-Oncology. Guy also makes substantial contributions in mentoring and teaching medical students and is on the Graduate Studies Committee for the School of Cancer Sciences. Guy has developed a considerable number of national and industry based collaborations with a mounting publication output (80+ peer reviewed publications) and is involved in the publication of national myeloma guidelines including being clinical lead for the ongoing NICE myeloma guideline. Moreover, he regularly peer reviews for a number of journals, grant holders and frequently serves as an external examiner. Finally, Guy regularly lectures to patients and relatives on Myeloma Info days organised by the patient support group Myeloma UK and is a Trustee for the Waldenstroms Macroglobulinaemia UK patient support group.
Pratt G. Lenalidomide and second malignancies in myeloma patients.Lancet Oncol. 2014 Mar;15(3):253-4.
Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Farsti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nthen MM, Mhleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Drner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013 Oct;45(10):1221-5.
Cobbold M, De La Pena H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. SciTransl Med. 2013 Sep 18;5(203):203ra125.doi: 10.1126/scitranslmed.3006061. PubMed PMID: 24048523.
Pratt G. Histone deacetylase inhibitors in multiple myeloma.Lancet Oncol. 2013 Oct;14(11):1038-9. doi: 10.1016/S1470-2045(13)70425-X. Epub 2013 Sep 19. PubMed PMID: 24055413.
Goodyear OC, Pearce H, Pratt G, Moss P. Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. Cancer ImmunolImmunother. 2011 Dec;60(12):1751-61.
Piper KP, Karanth M, McLarnon A, Kalk E, Khan N, Murray J, Pratt G, Moss PA. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. ClinExpImmunol. 2011 Nov;166(2):154-63.
HutchisonCA, Pratt G. Free light-chains and renal disorders: when small is worse. Lancet. 2010 Oct 9;376(9748):1220; author reply 1221-2.
Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Mol Cancer Ther. 2010 Jun;9(6):1574-82.
Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, Pearce C, Sant T, Drayson MT, Bunce CM. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia. 2009 Feb;23(2):292-304.
Goodyear OC, Pratt G, McLarnon A, Cook M, Piper K, Moss P. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood. 2008 Oct 15;112(8):3362-72.